Principles of Pharmacology

  • Jerry Avorn
  • Jerry H. Gurwitz


The proper use of medications represents one of the most important ways in which the practice of geriatric medicine differs from conventional medical care. Pharmacotherapy is perhaps the single most important medical intervention in the care of elderly patients, and its proper performance requires a special understanding of the unique pharmacologic properties of drugs in this population, as well as a grasp of the epidemiologic, sociocultural, and regulatory aspects of medication use in aging.


International Normalize Ratio Antipsychotic Drug Nursing Home Resident Psychoactive Drug Geriatric Medicine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Schmucker DL. Aging and drug disposition: an update. Pharmacol Rev. 1985; 37: 133–148.PubMedGoogle Scholar
  2. 2.
    Castleden CM, et al. The effect of ageing on drug absorption from the gut. Age Ageing. 1977; 6: 138–143.PubMedCrossRefGoogle Scholar
  3. 3.
    Schwartz JB. Clinical pharmacology. In: Hazzard WR, Bierman EL, Blass JP, et al., eds. Principles of Geriatric Medicine and Gerontology. 3rd ed. New York: McGraw- Hill; 1994.Google Scholar
  4. 4.
    Campion EW, deLabry LO, Glynn RJ. The effect of age on serum albumin in healthy males: report from the Normative Aging Study. J Gerontol. 1988; 43: M18 - M20.PubMedCrossRefGoogle Scholar
  5. 5.
    MacLennan WJ, Martin P, Mason BJ. Protein intake and serum albumin levels in the elderly. Gerontology. 1977; 23: 360–367.PubMedCrossRefGoogle Scholar
  6. 6.
    Conti MC, Goralnik JH, Salive ME, et al. Serum albumin level and physical disability as predictors of mortality in older persons. JAMA. 1994; 272: 1036–1042.CrossRefGoogle Scholar
  7. 7.
    Greenblatt DJ, Sellers EM, Koch-Weser J. Importance of protein binding for the interpretation of serum or plasma drug concentrations. J Clin Pharmacol. 1982; 22: 259–263.PubMedCrossRefGoogle Scholar
  8. 8.
    Frontera WR, Hughes VA, Lutz KJ, et al. A cross-sectional study of muscle strength and mass in 45- to 78-yr-old men and women. J Appl Physiol. 1991; 71: 644–650.PubMedGoogle Scholar
  9. 9.
    Mooney H, Roberts R, Cooksley WGE, et al. Alterations in the liver with aging. Clin Gastroenterol. 1985; 14: 757–771.PubMedGoogle Scholar
  10. 10.
    Vestal RE, Norris AH, Tobin JD, et al. Antipyrine metabolism in man: influence of age, alcohol, caffeine, and smoking. Clin Pharmacol Ther. 1975; 18: 425–432.PubMedGoogle Scholar
  11. 11.
    Rowe JW, Andres R, Tobin JD, et al. The effect of age on creatinine clearance in man. J Gerontol. 1976; 31: 155–163.PubMedCrossRefGoogle Scholar
  12. 12.
    Lindeman RD, Tobin JD, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985; 33: 278–285.PubMedGoogle Scholar
  13. 13.
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31–41.PubMedCrossRefGoogle Scholar
  14. 14.
    Friedman JR, Norman DC, Yoshikawa TT. Correlation of estimated renal function parameters versus 24-hour creatinine clearance in ambulatory elderly. J Am Geriatr Soc. 1989; 37: 145–149.PubMedGoogle Scholar
  15. 15.
    Greenblatt DJ, Divoll M, Harmatz JS, et al. Kinetics and clinical effects of flurazepam in young and elderly insomniacs. Clin Pharmacol Ther. 1981; 30: 475–486.PubMedCrossRefGoogle Scholar
  16. 16.
    Greenblatt DJ. Benzodiazepine hypnotics: sorting the pharmacokinetic facts. J Clin Psychiatry. 1991; 52 (suppl 9): 4–10.PubMedGoogle Scholar
  17. 17.
    Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA. 1989; 262: 3303–3307.PubMedCrossRefGoogle Scholar
  18. 18.
    Greenblatt DJ, Allen MD, Shader RL. Toxicity of high-dose flurazepam in the elderly. Clin Pharmacol Ther. 1977; 21: 355–361.PubMedGoogle Scholar
  19. 19.
    Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: therapeutic considerations (part I). Clin Pharmacokinet. 1991; 21: 165–177.PubMedCrossRefGoogle Scholar
  20. 20.
    Greenblatt DJ, Harmatz JS, Shapiro L, et al. Sensitivity to triazolam in the elderly. N Engl J Med. 1991; 324: 1691–1698.PubMedCrossRefGoogle Scholar
  21. 21.
    Reidenberg MM, Levy M, Warner H, et al. Relationship between diazepam dose, plasma level, age, and central nervous system depression. Clin Pharmacol Ther. 1978; 23: 371–374.PubMedGoogle Scholar
  22. 22.
    Castleden CM, George CF, Marcer D, et al. Increased sensitivity to nitrazepam in old age. Br Med J. 1977; 1: 10–12.PubMedCrossRefGoogle Scholar
  23. 23.
    Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: therapeutic considerations (part II). Clin Pharmacokinet. 1991; 21: 262–273.PubMedCrossRefGoogle Scholar
  24. 24.
    O’Malley K, Stevenson IH, Ward CA, et al. Determinants of anticoagulant control in patients receiving warfarin. Br J Clin Pharmacol 1977; 4: 309–314.PubMedCrossRefGoogle Scholar
  25. 25.
    Shephard AMM, Hewick DS, Moreland TA. Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol. 1977; 4: 315–320.CrossRefGoogle Scholar
  26. 26.
    Gurwitz JH, Avorn J, Ross-Degnan D, et al. Aging and the anticoagulant response to warfarin. Ann Intern Med. 1992; 116: 901–904.PubMedGoogle Scholar
  27. 27.
    Bellville JW, Forrest WH, Miller E, et al. Influence of age on pain relief from analgesics. JAMA. 1971; 217: 1835–1841.PubMedCrossRefGoogle Scholar
  28. 28.
    Kaiko RF. Age and morphine analgesia in cancer patients with postoperative pain. Clin Pharmacol Ther. 1980; 28: 823–826.PubMedCrossRefGoogle Scholar
  29. 29.
    Scott JC, Stanski DR. Decreased fentanyl and alfentanil dose requirements with age: a simultaneous pharmacokinetic and pharmacodynamic evaluation./Pharmacol Exp Ther. 1987; 240: 159–166.Google Scholar
  30. 30.
    Vestal RE, Wood AJJ, Shand DG. Reduced beta-adrenoreceptor sensitivity in the elderly. Clin Pharmacol Ther. 1979; 26: 181–186.PubMedGoogle Scholar
  31. 31.
    Avorn J, Everitt DE, Weiss S, et al. Increased antidepressant use in patients prescribed beta-blockers. JAMA. 1986; 255: 357–360.PubMedCrossRefGoogle Scholar
  32. 32.
    Thiessen BQ, Wallace SM, Blackburn JL, et al. Increased prescribing of antidepressants subsequent to beta-blocker therapy. Arch Intern Med. 1990; 150: 2286–2290.PubMedCrossRefGoogle Scholar
  33. 33.
    Greenblatt DJ, Shader RI, Harmatz JS. Implications of altered drug disposition in the elderly: studies of benzodiazepines. J Clin Pharmacol. 1989; 29: 866–872.PubMedCrossRefGoogle Scholar
  34. 34.
    Berlinger WG, Goldberg MJ, Spector R, et al. Diphenhydramine: kinetics and psychomotor effects in elderly women. Clin Pharmacol Ther. 1982; 32: 387–391.PubMedCrossRefGoogle Scholar
  35. 35.
    Nolan L, O’Malley K. Prescribing for the elderly. Part I: Sensitivity of the elderly to adverse drug reactions. J Am GeriatrSoc. 1988; 36: 142–149.Google Scholar
  36. 36.
    Gurwitz JH, Avorn J. The ambiguous relation between aging and adverse drug reactions. Ann Intern Med. 1991; 114: 956–966.PubMedGoogle Scholar
  37. 37.
    Larson EB, Kukull WA, Buchner D, et al. Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Intern Med. 1987; 107: 169–173.PubMedGoogle Scholar
  38. 38.
    Cantu TG, Korek JS. Central nervous system reactions to histamine-2 receptor blockers. Ann Intern Med. 1991; 114: 1027–1034.PubMedGoogle Scholar
  39. 39.
    Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med. 1987; 316: 363–369.PubMedCrossRefGoogle Scholar
  40. 40.
    Avorn J, Monane M, Everitt DE, et al. Clinical assessment of extrapyramidal signs in nursing home patients given antipsychotic medication. Arch Intern Med. 1994; 154: 1113–1117.PubMedCrossRefGoogle Scholar
  41. 41.
    Avorn J, Bohn RL, Mogun H, et al. Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study. Am J Med. 1995; 99: 48–54.PubMedCrossRefGoogle Scholar
  42. 42.
    Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med. 1987; 147: 1561–1564.PubMedCrossRefGoogle Scholar
  43. 43.
    Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994; 120: 897–902.PubMedGoogle Scholar
  44. 44.
    Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation: a multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med. 1993; 118: 511–520.PubMedGoogle Scholar
  45. 45.
    Kalish S, Gurwitz JH, Avorn J. Anticoagulant therapy in the elderly. Primary Cardiology. 1993; 7: 34–42.Google Scholar
  46. 46.
    Landefeld CS, Anderson PA. Guideline-based consultation to prevent anticoagulant-related bleeding. A randomized, controlled trial in a teaching hospital. Ann Intern Med. 1992; 116: 829–837.PubMedGoogle Scholar
  47. 47.
    Becker RC, Ansell J. Antithrombotic therapy: an abbreviated reference for clinicians. Arch Intern Med. 1995; 155: 149–161.PubMedCrossRefGoogle Scholar
  48. 48.
    Gurwitz JH, Avorn J, Ross-Degnan D, et al. Nonsteroidal anti-inflammatory drug-associated azotemia in the very old. JAMA. 1990; 264: 471–475.PubMedCrossRefGoogle Scholar
  49. 49.
    Bollini P, Garcia Rodriguez LA, Perez Gutthann S, et al. The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal antiinflammatory drugs on upper gastrointestinal tract disease. Arch Intern Med. 1992; 152: 1289–1295.PubMedCrossRefGoogle Scholar
  50. 50.
    Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med. 1993; 119: 1277–1280.Google Scholar
  51. 51.
    Bradley JD, Brandt KD, Katz BP, et al. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med. 1991; 325: 87–91.PubMedCrossRefGoogle Scholar
  52. 52.
    Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA. 1994; 272: 1845–1850.PubMedCrossRefGoogle Scholar
  53. 53.
    Begg CB, Carbone PP. Clinical trials and drug toxicity in the elderly: the experience of the Eastern Cooperative Oncology Group. Cancer. 1983; 52: 1986–1992.PubMedCrossRefGoogle Scholar
  54. 54.
    Christman K, Muss HB, Case LD, et al. Chemotherapy of metastatic breast cancer in the elderly: the Piedmont Oncology Association Experience. JAMA. 1992; 268: 57–62.PubMedCrossRefGoogle Scholar
  55. 55.
    Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981; 304: 10–15.PubMedCrossRefGoogle Scholar
  56. 56.
    Hryniuk WM, Levine MN, Levin L. Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer. Natl Cancer Inst Monogr. 1986; 1: 87–94.Google Scholar
  57. 57.
    Lipschitz DA. Aging of the hematopoietic system. In: Hazzard WR, Andres R, Bierman EL, Blass JP, eds. Principles of Geriatric Medicine and Gerontology. 2nd ed. New York: McGraw-Hill; 1990.Google Scholar
  58. 58.
    Greenblatt DJ1, Harmatz JS, Zinny MA, et al. Effect of gradual withdrawal on the rebound sleep disorder after discontinuation of triazolam. N Engl J Med. 1987; 317: 722–728.CrossRefGoogle Scholar
  59. 59.
    Busto U, Sellers EM, Naranjo CA, et al. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med. 1986; 315: 854–859.PubMedCrossRefGoogle Scholar
  60. 60.
    Danielson M, Lundback M. Withdrawal of antihypertensive drugs in mild hypertension. Acta Med Scand. 1981; 646 (suppl 1): 127–131.Google Scholar
  61. 61.
    Fleg JL, Gottlieb SH, Lakatta EG. Is digoxin really important in treatment of compensated heart failure? A placebo-controlled crossover study in patients with sinus rhythm. Am J Med. 1982; 73: 244–250.PubMedCrossRefGoogle Scholar
  62. 62.
    Gheorghiade M, Beller GA. Effect of discontinuing maintenance digoxin therapy in patients with ischemic heart disease and congestive heart failure in sinus rhythm. Am J Cardiol 1983; 51: 1243–1250.PubMedCrossRefGoogle Scholar
  63. 63.
    Yusuf S, Garg R, Held P, et al. Need for a large randomized trial to evaluate the effects of digitalis on morbidity and mortality in congestive heart failure. Am J Cardiol. 1992; 69: 64G - 70G.PubMedCrossRefGoogle Scholar
  64. 64.
    Forman DE, Coletta D, Kenny D, et al. Clinical issues related to discontinuing digoxin therapy in elderly nursing home patients. Arch Intern Med. 1991; 151: 2194–2198.PubMedCrossRefGoogle Scholar
  65. 65.
    Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med. 1993; 329: 1–7.PubMedCrossRefGoogle Scholar
  66. 66.
    Sackett DL, Snow JC. The magnitude of compliance and noncompliance. In: Haynes RB, Taylor DW, Sackett DL, eds. Compliance in Health Care. Baltimore: The Johns Hopkins University Press; 1979: 11–12.Google Scholar
  67. 67.
    Simonson W. Medications and the Elderly: A Guide for Promoting Proper Use. Rockville, MD: Aspen Systems Corp; 1984.Google Scholar
  68. 68.
    Ostrom JR, Hammarlund ER, Christensen DB, et al. Medication usage in the elderly population. Med Care. 1985; 23: 157–164.PubMedCrossRefGoogle Scholar
  69. 69.
    Hammarlund ER, Ostrom JR, Kethley AJ. The effects of drug counseling and other educational strategies on drug utilization of the elderly. Med Care. 1985; 23: 165–170.PubMedCrossRefGoogle Scholar
  70. 70.
    Darnell JC, Murray MD, Martz BL, et al. Medication use by ambulatory elderly: an in-home survey. J Am Geriatr Soc. 1986; 34: 1–4.PubMedGoogle Scholar
  71. 71.
    German PS, Klein LE, McPhee SJ, et al. Knowledge of and compliance with drug regimens in the elderly. J Am Geriatr Soc. 1982; 30: 568–571.PubMedGoogle Scholar
  72. 72.
    Kendrick R, Bayne JRD. Compliance with prescribed medication by elderly patients. Can Med Assoc J. 1982; 127: 961–962.PubMedGoogle Scholar
  73. 73.
    Gurwitz JH, Glynn RJ, Monane M, et al. Treatment for glaucoma: adherence by the elderly. Am J Public Health. 1993; 83: 711–716.PubMedCrossRefGoogle Scholar
  74. 74.
    Mazzullo J. The nonpharmacologic basis of therapeutics. Clin Pharmacol Ther. 1972; 13: 157–158.PubMedGoogle Scholar
  75. 75.
    Mitchell JB. Physician visits to nursing homes. Gerontolo-gist. 1982; 22: 45–48.CrossRefGoogle Scholar
  76. 76.
    Gurwitz JH, Soumerai SB, Avorn J. Improving medication prescribing and utilization in the nursing home. J Am Geriatr Soc. 1990; 38: 542–552.PubMedGoogle Scholar
  77. 77.
    Anon. Conditions of participation-pharmaceutical services. Federal Register. 1974; 39: 12–17.Google Scholar
  78. 78.
    Winograd CH, Pawlson LG. OBRA 87-a commentary. J Am Geriatr Soc. 1991; 39: 724–726.PubMedGoogle Scholar
  79. 79.
    Elon R, Pawlson LG. The impact of OBRA on medical practice within nursing facilities. J Am Geriatr Soc. 1992; 40: 958–963.PubMedGoogle Scholar
  80. 80.
    Shorr RI, Fought RL, Ray WA. Changes in antipsychotic drug use in nursing homes during implementation of OBRA-87 regulations. JAMA. 1994; 271: 358–362.PubMedCrossRefGoogle Scholar
  81. 81.
    Rovner BW, Edelman BA, Cox MP, et al. The impact of antipsychotic drug regulations on psychotropic prescribing practices in nursing homes. Am J Psychiatry. 1992; 149: 1390–1392.PubMedGoogle Scholar
  82. 82.
    Ray WA, Federspiel CF, Schaffner W. A study of antipsychotic drug use in nursing homes: epidemiologic evidence suggesting misuse. Am J Public Health. 1980; 70: 485–491.PubMedCrossRefGoogle Scholar
  83. 83.
    Ingman SR, Lawron IR, Pierpaoli PG, et al. A survey of the prescribing and administration of drugs in a long-term care institution for the elderly. J Am Geriatr Soc. 1975; 23: 309–316.PubMedGoogle Scholar
  84. 84.
    Beers M, Avorn J, Soumerai SB, et al. Psychoactive medication use in intermediate-care facilities. JAMA. 1988; 260: 3016–3020.PubMedCrossRefGoogle Scholar
  85. 85.
    Buck J A. Psychotropic drug practice in nursing homes. J Am Geriatr Soc. 1988; 36: 409–418.PubMedGoogle Scholar
  86. 86.
    Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc. 1990; 38: 553–563.PubMedGoogle Scholar
  87. 87.
    Avorn J, Soumerai SB, Everitt DE, et al. A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes. N Engl J Med. 1992; 327: 168–173.PubMedCrossRefGoogle Scholar
  88. 88.
    Everitt DE, Fields DR, Soumerai SS, et al. Resident behavior and staff distress in the nursing home. J Am Geriatr Soc. 1991; 39: 792–798.PubMedGoogle Scholar
  89. 89.
    Ray WA, Taylor JA, Meador KH, et al. Reducing antipsychotic drug use in nursing homes: a controlled trial of provider education. Arch Intern Med. 1993; 153: 713–721.PubMedCrossRefGoogle Scholar
  90. 90.
    Svarstad BL, Mount JK. Nursing home resources and tranquilizer use among the institutionalized elderly. J Am Geriatr Soc. 1991; 39: 869–875.PubMedGoogle Scholar
  91. 91.
    Taggart HM, Alderdice JM. Fatal cholestatic jaundice in elderly patients taking benoxaprofen. Br Med J Clin Res. 1982; 284: 1372.CrossRefGoogle Scholar
  92. 92.
    SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991; 265: 3255–3264.CrossRefGoogle Scholar
  93. 93.
    Gurwitz JH, Col NF, Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. JAMA. 1991; 268: 1417–1422.CrossRefGoogle Scholar
  94. 94.
    Guideline for the Study of Drugs Likely to be Used in the Elderly. Rockville, MD: Center for Drug Evaluation and Research, Food and Drug Administration; 1989.Google Scholar
  95. 95.
    Lohr JB, Jeste DV, Harris MJ, Salzman C. Treatment of disordered behavior. In: Salzman C, ed. Clinical Geriatric Psychopharmacology. 2nd ed. Baltimore: Williams and Wilkins; 1992: 79–113.Google Scholar
  96. 96.
    Greenblatt DJ, Sellers EM, Shader RI. Drug disposition in old age. N Engl J Med. 1982; 306: 1081–1088.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Jerry Avorn
  • Jerry H. Gurwitz

There are no affiliations available

Personalised recommendations